Login to Your Account

Basilea Hands Off Eczema Drug Toctino to GSK; $227M Up Front

By Cormac Sheridan
Staff Writer

Wednesday, June 13, 2012
In a deal that is an asset disposal in all but name, Basilea Pharmaceutica AG is banking £146 million up front (US$226.8 million) and could get between £30 million and £50 million more in regulatory milestones from a global agreement on its hand eczema drug Toctino (alitretinoin) with Stiefel, the dermatology subsidiary of GlaxoSmithKline plc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription